Pmda - Pharmaceuticals and Medical Devices Agency
Menu
Close

Post-marketing Safety Measures

Revisions of PRECAUTIONS (FY2025)

Date Nonproprietary name Detailed information on revisions of PRECAUTIONS
(from MHLW)
Summary of
investigation results
(from PMDA)
Reference article note)
(if applicable)
April 8, 2025
  • Desmopressin acetate hydrate (injections)
PRECAUTIONS
[17.7 KB]
Summary of
Investigation
[84.7 KB]
  • Imeglimin hydrochloride
PRECAUTIONS
[42.2 KB]
Summary of
Investigation
[66.0 KB]
  • Enzalutamide
PRECAUTIONS
[20.8 KB]
Summary of
Investigation
[62.2 KB]
  • Nirmatrelvir/ritonavir
PRECAUTIONS
[24.7 KB]
Summary of
Investigation
[62.2 KB]


Note) "Important Safety Information" in Pharmaceuticals and Medical Devices Safety Information (PMDSI)